Sector Atlas · Updated June 30, 2026

The Healthcare & MedTech Stock Atlas

Every major publicly traded U.S. healthcare specialty, mapped with live analyst sentiment, direct company links, sample portfolios from aggressive to conservative, and the emerging names with the most exponential upside.

❤️ Cardiology & Cardiovascular Surgery 🦴 Orthopedics 🔬 Diagnostics & Imaging 🤖 Surgical Robotics 💊 Large-Cap Pharma 🧬 Biotech 🛡️ Managed Care 🏥 Hospitals 💻 Healthcare IT 🩸 Diabetes Care 🦷 Dental & Vision ✅ All Buy Ratings 📊 Sample Portfolios 🎗 Oncology 🧠 Neurology & CNS 🫁 Respiratory & Sleep 🦋 Rare Disease 🐾 Animal Health 🌸 Women’s Health 🫀 GI & Gastroenterology 💧 Renal & Nephrology 🚀 Emerging Growth

Before you read on: this page is for general informational and educational purposes only. It is not investment advice, and the author is not a financial advisor. Analyst consensus ratings and price targets are time-sensitive snapshots, sourced from stockanalysis.com, TipRanks, MarketBeat, Public.com, and Simply Wall St as of June 29–30, 2026, and can shift within days around earnings or FDA news. On the new "Price" column: bolded values are recent reference prices captured during research; every other ticker links straight to a live quote instead of showing a number that could already be stale. Always verify current data before acting, and speak with a licensed advisor about your own situation.

1

Cardiology & Cardiovascular Devices

Pacemakers, stents, structural heart valves, and the surgical robots edging into the cath lab.

Ticker	Company	Cap	Rating	Price	Target	What they do
MDT	Medtronic	Large	Buy	$81	~$98–$108	Pacemakers, defibrillators, cardiac ablation tech
ABT	Abbott Laboratories	Large	Buy	$92.71	~$128	Cardiovascular, diabetes & diagnostics conglomerate
BSX	Boston Scientific	Large	Hold	$42.47	~$115–$130	Electrophysiology (FARAPULSE), structural heart (WATCHMAN)
EW	Edwards Lifesciences	Large	Mixed	$90.71	—	Structural heart valves (TAVR), critical care monitoring
ATRC	AtriCure	Small	Mixed	Check live price	—	Atrial fibrillation surgical ablation devices
CRDL	Cardiol Therapeutics	Small	Strong Buy	$0.99	~$8	Clinical-stage CBD-based anti-inflammatory heart drugs
OBIO	Orchestra BioMed	Small	Speculative	Check live price	—	Bioelectronic hypertension therapy (AVIM), partnered with Medtronic
JNJ	Johnson & Johnson (Abiomed & Shockwave)	Large	Buy	$254	~$257	Owns Impella heart pumps (Abiomed) and intravascular lithotripsy (Shockwave) for calcified artery treatment
PEN	Penumbra ⚠ Acq. by BSX Jan 2026	Mid	Buy-leaning	$317.63	—	Thrombectomy systems for vascular and neurovascular clot removal
NARI	Inari Medical	Mid	Buy-leaning	Check live price	—	Catheter-based devices to remove blood clots in venous thromboembolism (DVT/PE)
SILK	Silk Road Medical	Small	Mixed	Check live price	—	TransCarotid Artery Revascularization (TCAR) system for stroke prevention
AORT	Artivion (formerly CryoLife)	Small/Mid	Buy-leaning	Check live price	—	Aortic disease devices, cardiac surgery grafts, and tissue products
LIVN	LivaNova	Mid	Mixed	Check live price	—	Cardiopulmonary bypass/perfusion systems used in open-heart surgery
HAE	Haemonetics	Mid	Buy-leaning	Check live price	—	Blood management and autotransfusion systems used during cardiac surgery
MMSI	Merit Medical Systems	Small/Mid	Buy-leaning	Check live price	—	Cardiovascular catheters, guidewires, and embolization devices
ANGO	AngioDynamics	Small	Mixed	Check live price	—	Vascular access devices, peripheral vascular and venous disease treatment
SRDX	Surmodics	Small	Mixed	Check live price	—	Drug-coated balloon technology and coatings licensed to cardiovascular device makers
ITGR	Integer Holdings	Mid	Buy-leaning	Check live price	—	Manufactures components (batteries, leads) used inside pacemakers and defibrillators
IRTC	iRhythm Technologies	Small/Mid	Buy-leaning	Check live price	—	Zio wearable patch for ambulatory cardiac arrhythmia monitoring
CNMD	CONMED	Small/Mid	Mixed	Check live price	—	Surgical devices used across cardiac and general surgery procedures
INSP	Inspire Medical Systems	Mid	Buy-leaning	$41.75	—	Implantable neurostimulation for sleep apnea, a major cardiovascular risk factor
GETI-B.ST	Getinge (Stockholm-listed)	Mid/Large	Mixed	Check live price	—	Cardiopulmonary support, intra-aortic balloon pumps, surgical workflow equipment

2

Orthopedics

Joint replacements, spine hardware, and the robotic navigation systems reshaping the OR.

Ticker	Company	Cap	Rating	Price	Target	What they do
SYK	Stryker	Large	Buy	$304.69	—	Orthopedic implants, Mako robotics, MedSurg
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	Knee/hip implants, ROSA robotics, spine, dental
JNJ	J&J DePuy Synthes	Large	Buy	$254	~$257	Orthopedic reconstruction & trauma
GMED	Globus Medical	Mid	Buy-leaning	Check live price	—	Spine implants, ExcelsiusGPS robotic spine surgery
SNN	Smith+Nephew	Mid	Hold	Check live price	—	Orthopedics, sports medicine, wound care
AXGN	Axogen	Small	Buy-leaning	Check live price	—	Peripheral nerve repair
ATEC	Alphatec Holdings	Small	Buy-leaning	Check live price	—	Spine surgery technology
ENOV	Enovis	Mid	Mixed	Check live price	—	Reconstructive & prevention/recovery orthopedics

3

Diagnostics & Imaging

Lab testing networks, imaging centers, and the liquid-biopsy upstarts chasing earlier cancer detection.

Ticker	Company	Cap	Rating	Price	Target	What they do
DGX	Quest Diagnostics	Large	Mixed (Hold-leaning)	$195	~$190–$220	Nationwide clinical lab testing
LH	Labcorp	Large	Buy-leaning	Check live price	—	Lab testing & drug development services
GEHC	GE HealthCare	Large	Buy-leaning	$63.72	—	MRI, CT, ultrasound imaging equipment
TMO	Thermo Fisher Scientific	Large	Buy	Check live price	—	Life sciences tools, diagnostics, lab equipment
DHR	Danaher	Large	Buy-leaning	Check live price	—	Diagnostics, life sciences, biotech tools
RDNT	RadNet	Small/Mid	Buy-leaning	$58	—	Outpatient imaging + AI imaging division
GH	Guardant Health	Mid	Buy	$140	—	Liquid biopsy cancer genomic testing
EXAS	Exact Sciences	Mid	Buy-leaning	Check live price	—	Cancer screening (Cologuard)
NTRA	Natera	Mid	Buy	Check live price	—	Genetic testing, prenatal & oncology
TXG	10x Genomics	Small	Mixed	Check live price	—	Single-cell and spatial genomics tools

4

Surgical Robotics & Broad MedTech

The da Vinci-class platforms hospitals are betting their capital budgets on.

Ticker	Company	Cap	Rating	Price	Target	What they do
ISRG	Intuitive Surgical	Large	Strong Buy	$412	~$580–$615	da Vinci & Ion robotic surgical platforms
MDT	Medtronic	Large	Buy	$81	~$98–$108	Hugo robotic-assisted surgery system
SYK	Stryker	Large	Buy-leaning	$304.69	—	Mako robotic orthopedic surgery
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	ROSA robotic knee/hip navigation
ASXC	Asensus Surgical	Small	Speculative	Check live price	—	Digital laparoscopic surgical robotics
TMDX	TransMedics	Mid	Buy-leaning	Check live price	—	Organ transplant preservation/logistics tech
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL) for vision

5

Pharmaceuticals (Large-Cap)

GLP-1s, oncology blockbusters, and the patent-cliff dramas driving 2026 sentiment.

Ticker	Company	Cap	Rating	Price	Target	What they do
LLY	Eli Lilly	Large (~$700B+)	Strong Buy	$1,117	~$1,220–$1,250	GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound)
JNJ	Johnson & Johnson	Large (~$565B)	Buy	$254	~$257	Diversified pharma, immunology, oncology, MedTech
ABBV	AbbVie	Large (~$383B)	Buy/Hold	Check live price	—	Immunology post-Humira (Skyrizi, Rinvoq)
MRK	Merck & Co.	Large (~$302B)	Hold	Check live price	—	Keytruda oncology franchise, facing patent cliff
AZN	AstraZeneca	Large (~$291B)	Buy-leaning	Check live price	—	Oncology, cardiovascular/metabolic, biologics
PFE	Pfizer	Large	Hold	$24.29	—	Diversified pharma, post-COVID turnaround
BMY	Bristol Myers Squibb	Large	Hold-leaning	Check live price	—	Oncology, immunology
NVO	Novo Nordisk	Large	Mixed	Check live price	—	GLP-1 drugs (Ozempic/Wegovy)
GILD	Gilead Sciences	Large	Buy-leaning	Check live price	—	HIV franchise, growing oncology (Trodelvy)
AMGN	Amgen	Large	Buy-leaning	Check live price	—	Immunology, oncology, obesity pipeline (MariTide)

6

Biotech (Mid/Small-Cap)

Gene therapy, gene editing, and the autoimmune/rare-disease names with binary catalysts ahead.

Ticker	Company	Cap	Rating	Price	Target	What they do
VRTX	Vertex Pharmaceuticals	Large	Buy	Check live price	—	Cystic fibrosis monopoly, Casgevy gene therapy
REGN	Regeneron Pharmaceuticals	Large	Buy-leaning	Check live price	—	Eylea eye drug, Dupixent (with Sanofi)
ARGX	argenx	Mid/Large	Buy	Check live price	—	FcRn blocker Vyvgart across autoimmune indications
SRPT	Sarepta Therapeutics	Mid	Hold	$18	~$19	Gene therapy for Duchenne muscular dystrophy
NTLA	Intellia Therapeutics	Small/Mid	Speculative	Check live price	—	In vivo CRISPR gene editing
CRSP	CRISPR Therapeutics	Mid	Buy	Check live price	—	Casgevy gene-editing therapy (with Vertex)
KRYS	Krystal Biotech	Mid	Buy	Check live price	—	Gene therapy gel Vyjuvek for rare skin disease
RNA	Avidity Biosciences	Small/Mid	Buy-leaning	Check live price	—	RNA-targeted therapeutics
VERA	Vera Therapeutics	Small	Speculative	Check live price	—	Autoimmune kidney disease therapeutics
XENE	Xenon Pharmaceuticals	Small/Mid	Buy	Check live price	—	KV7 channel opener for epilepsy/neuro
VKTX	Viking Therapeutics	Small/Mid	Buy	Check live price	—	Oral & injectable GLP-1 obesity candidates
CRNX	Crinetics Pharmaceuticals	Small/Mid	Buy	Check live price	—	Oral therapies for endocrine disorders
ABVX	Abivax SA	Mid	Strong Buy	$96.15 (+37% today 6/30)	~$108–$187 (avg ~$149)	French clinical-stage biotech developing obefazimod, an RNA-targeting anti-inflammatory drug in Phase 3 for ulcerative colitis; NDA filing targeted Q4 2026; 12 analysts Buy, avg target ~$149, Guggenheim $175 Best Idea

7

Managed Care & Health Insurers

Medical cost ratios, Medicare Advantage rates, and the 2026 sector-wide relief rally.

Ticker	Company	Cap	Rating	Price	Target	What they do
UNH	UnitedHealth Group	Large	Buy	Check live price	~$357–$450	Largest U.S. insurer; UnitedHealthcare + Optum
ELV	Elevance Health	Large	Buy/Neutral	Check live price	~$405	Blue Cross Blue Shield plans, Medicaid/MA
HUM	Humana	Mid/Large	Mixed	Check live price	~$210–$254	Medicare Advantage-focused insurer
CI	Cigna Group	Large	Mixed	Check live price	~$304–$400	Commercial insurance + Evernorth/Express Scripts
CVS	CVS Health	Large	Buy-leaning	Check live price	—	Retail pharmacy, Aetna insurance, Caremark PBM
CNC	Centene	Mid	Mixed	Check live price	—	Medicaid/ACA marketplace insurer
MOH	Molina Healthcare	Mid	Mixed	Check live price	—	Medicaid/Medicare/Marketplace insurer
OSCR	Oscar Health	Small	Speculative	Check live price	—	Tech-driven ACA marketplace insurer

8

Hospitals & Health Systems

For-profit hospital operators navigating Medicaid policy risk and wage inflation.

Ticker	Company	Cap	Rating	Price	Target	What they do
HCA	HCA Healthcare	Large	Buy	$315	~$415–$520	190+ acute-care hospitals across the U.S. & England
UHS	Universal Health Services	Mid/Large	Buy-leaning	Check live price	—	Acute care + behavioral health hospitals
THC	Tenet Healthcare	Mid	Mixed	$171	—	Hospitals, ambulatory surgery centers
CYH	Community Health Systems	Small	Cautious	Check live price	—	Community hospital operator
ACHC	Acadia Healthcare	Small/Mid	Mixed	$25	—	Behavioral health & substance use facilities
DVA	DaVita	Mid	Mixed	Check live price	—	Dialysis/kidney care centers
EHC	Encompass Health	Mid	Buy-leaning	Check live price	—	Inpatient rehabilitation hospitals

9

Healthcare IT & Digital Health

Clinical software, telehealth, and AI tools rapidly resetting margin expectations.

Ticker	Company	Cap	Rating	Price	Target	What they do
VEEV	Veeva Systems	Large	Buy	Check live price	—	Cloud software for life sciences (CRM, regulatory)
DOCS	Doximity	Mid	Volatile / Buy-leaning	Check live price	~$40–$65	Physician network + AI tools (DocsGPT, Scribe)
TDOC	Teladoc Health	Small/Mid	Hold/Cautious	Check live price	—	Virtual care, BetterHelp mental health platform
PHR	Phreesia	Small/Mid	Mixed	Check live price	—	Patient intake/engagement software
OMCL	Omnicell	Small/Mid	Buy-leaning	Check live price	—	Medication management automation
HQY	HealthEquity	Mid	Mixed	Check live price	—	HSA/consumer-directed healthcare accounts
WAY	Waystar Holding	Mid	Buy-leaning	Check live price	—	Healthcare payments & revenue cycle software
TEM	Tempus AI	Mid	Speculative	Check live price	—	AI-driven precision medicine platform
GDRX	GoodRx Holdings	Small	Mixed	Check live price	—	Prescription discount platform

10

Diabetes Care & Endocrinology Devices

CGMs and insulin pumps fighting the GLP-1 demand-destruction narrative.

Ticker	Company	Cap	Rating	Price	Target	What they do
DXCM	DexCom	Mid/Large	Buy	$71	~$64–$95	Continuous glucose monitoring (CGM) systems
PODD	Insulet	Mid/Large	Buy	$154	~$190	Omnipod tubeless insulin pump
TNDM	Tandem Diabetes Care	Small/Mid	Buy	$23	~$28–$31	t:slim X2 & Mobi insulin pumps
BBNX	Beta Bionics	Small	Hold/Neutral	$16	—	iLet bionic pancreas automated insulin delivery
ABT	Abbott (Diabetes Care)	Large	Buy	$92.71	~$128	FreeStyle Libre CGM franchise
SENS	Senseonics	Small	Speculative	Check live price	—	Long-term implantable CGM sensors

11

Dental & Vision

Clear aligners, contact lenses, and the eye-care names riding elective-procedure demand.

Ticker	Company	Cap	Rating	Price	Target	What they do
ALGN	Align Technology	Mid/Large	Mixed	$167	—	Invisalign clear aligners, iTero scanners
XRAY	Dentsply Sirona	Small/Mid	Mixed	$10	—	Dental equipment, consumables, technology
NVST	Envista Holdings	Mid	Buy-leaning	$30	~$28	Nobel Biocare, Ormco, DEXIS dental brands
COO	The Cooper Companies	Large	Buy-leaning	Check live price	~$91	CooperVision contact lenses, CooperSurgical
ALC	Alcon	Large	Buy-leaning	Check live price	—	Surgical & vision care eye products
BLCO	Bausch + Lomb	Mid	Mixed	Check live price	—	Eye health: surgical, vision care, pharma
HSIC	Henry Schein	Mid/Large	Hold-leaning	Check live price	—	Distributor of dental & medical products
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL)

12

Oncology

From checkpoint inhibitors and ADCs to CAR-T, liquid biopsy, and radiation oncology — the sector with the largest pipeline of any therapeutic area.

Ticker	Company	Cap	Rating	Price	Target	What they do
MRK	Merck & Co.	Large	Buy-leaning	~$113	~$122	Keytruda (#1 selling cancer drug globally), Gardasil HPV vaccine, facing 2028 patent cliff
AZN	AstraZeneca	Large	Buy	~$86	—	Tagrisso (NSCLC), Calquence (lymphoma), Enhertu ADC (breast/gastric cancer) with Daiichi Sankyo
BMY	Bristol Myers Squibb	Large	Hold-leaning	~$60	—	Opdivo & Yervoy (I-O checkpoint inhibitors), Revlimid (blood cancer), navigating biosimilar erosion
GILD	Gilead Sciences	Large	Buy-leaning	~$116	~$145	Trodelvy ADC (breast/bladder cancer), Yescarta CAR-T (lymphoma), growing oncology franchise
NUVL	Nuvalent	Mid	Buy	—	—	Next-generation kinase inhibitors for ROS1+ and ALK+ NSCLC; highly selective brain-penetrant design
IOVA	Iovance Biotherapeutics	Mid	Buy-leaning	—	—	Amtagvi: first TIL (tumor-infiltrating lymphocyte) therapy approved by FDA for melanoma
LEGN	Legend Biotech	Mid	Buy	—	—	Carvykti BCMA CAR-T therapy (with J&J) for multiple myeloma
RVMD	Revolution Medicines	Mid	Buy	—	—	RAS(ON) inhibitors targeting KRAS-driven cancers including pancreatic and colorectal
MRUS	Merus	Small/Mid	Buy-leaning	—	—	Bispecific antibody platform; Zenocutuzumab (NRG1 fusion cancers) recently FDA-approved
ARAY	Accuray	Small	Mixed	—	—	CyberKnife and TomoTherapy radiation oncology treatment systems
NKTR	Nektar Therapeutics	Small	Mixed	—	—	IL-2 pathway immuno-oncology drug conjugates

13

Neurology & Central Nervous System (CNS)

MS, Alzheimer's, epilepsy, depression, ALS, and the gene-therapy wave reshaping neurological care.

Ticker	Company	Cap	Rating	Price	Target	What they do
BIIB	Biogen	Large	Hold-leaning	~$147	—	MS therapies (Tysabri, Tecfidera), Leqembi Alzheimer's drug (with Eisai); navigating post-aducanumab challenges
AXSM	Axsome Therapeutics	Mid	Buy	—	—	Auvelity (MDD), Sunosi (narcolepsy/hypersomnia), Symbravo (migraine); CNS commercial-stage company
ACAD	ACADIA Pharmaceuticals	Mid	Buy-leaning	—	—	Nuplazid (Parkinson's psychosis), Daybue (Rett syndrome), focused CNS rare-disease pipeline
ALKS	Alkermes	Mid	Mixed	—	—	Vivitrol (opioid/alcohol dependence), Aristada (schizophrenia), LYBALVI (schizophrenia/bipolar)
IONS	Ionis Pharmaceuticals	Mid	Buy-leaning	—	—	Antisense oligonucleotide platform; Spinraza (SMA), eplontersen (TTR amyloidosis), broad neurology pipeline
PRAX	Praxis Precision Medicine	Small/Mid	Buy	—	—	Ion channel modulators for epilepsy and neuropsychiatric disorders; multiple late-stage assets
TSHA	Taysha Gene Therapies	Small	Speculative	—	—	AAV-based gene therapies for monogenic CNS diseases including SLC13A5 deficiency
NUVB	Nuvation Bio	Small	Speculative	—	—	CNS-penetrant oncology drugs; taletrectinib for ROS1/NTRK cancers with brain metastases
XENE	Xenon Pharmaceuticals	Small/Mid	Buy	—	—	KV7 potassium channel openers for epilepsy and psychiatric disorders; Phase 3 readouts near-term

14

Respiratory & Sleep Medicine

COPD, asthma, pulmonary fibrosis, sleep apnea devices, and portable oxygen — a sector with recurring device replacement and biologics growth.

Ticker	Company	Cap	Rating	Price	Target	What they do
RMD	ResMed	Large	Buy	~$244	—	CPAP/BiPAP devices and cloud-connected respiratory care platforms for sleep apnea and COPD
VRNA	Verona Pharma	Mid	Buy	—	—	Ohtuvayre (ensifentrine) FDA-approved for COPD; first new COPD mechanism in 20 years
INGN	Inogen	Small	Mixed	—	—	Portable oxygen concentrators for chronic respiratory disease patients at home and on-the-go
INSP	Inspire Medical Systems	Mid	Buy-leaning	$41.75	—	Inspire upper-airway stimulation neurostimulator for sleep apnea patients who cannot tolerate CPAP
GERN	Geron Corporation	Small	Mixed	—	—	Rytelo (imetelstat) — telomerase inhibitor for low-risk myelodysplastic syndromes; first approved telomerase inhibitor
LUNG	Pulmonx	Small	Mixed	—	—	Zephyr Endobronchial Valve for minimally invasive treatment of severe emphysema
GOSS	Gossamer Bio	Small	Speculative	—	—	Seralutinib inhaled therapy for pulmonary arterial hypertension; Phase 3 stage

15

Rare Disease & Orphan Drugs

High-price, high-margin therapies for ultra-rare conditions — pricing power, limited competition, and faster FDA pathways define this sub-sector.

Ticker	Company	Cap	Rating	Price	Target	What they do
BMRN	BioMarin Pharmaceutical	Large	Buy-leaning	—	—	Enzyme replacement and gene therapies for rare genetic diseases: PKU, hemophilia A (Roctavian), achondroplasia
RARE	Ultragenyx Pharmaceutical	Mid	Buy	—	—	Rare metabolic diseases; Crysvita (XLH), Dojolvi (LC-FAOD), Evkeeza (homozygous familial hypercholesterolemia)
PTCT	PTC Therapeutics	Mid	Mixed	—	—	Translarna (Duchenne muscular dystrophy), Translarna gene-therapy pipeline, rare neurological disorders
ARWR	Arrowhead Pharmaceuticals	Mid	Buy	—	—	RNAi therapeutics for rare liver disease (plozasiran for hypertriglyceridemia), respiratory, and cardiometabolic
ALNY	Alnylam Pharmaceuticals	Large	Buy	—	—	RNAi pioneer; Onpattro, Givlaari, Oxlumo, Amvuttra (TTR amyloidosis cardiomyopathy) and growing commercial portfolio
SRPT	Sarepta Therapeutics	Mid	Hold	~$18	~$19	Elevidys gene therapy and exon-skipping drugs for Duchenne muscular dystrophy; safety overhang on stock
BLUE	bluebird bio	Small	Speculative	—	—	Gene therapies for beta-thalassemia (Zynteglo) and sickle cell disease (Lyfgenia); commercialization-stage
SWTX	SpringWorks Therapeutics	Small/Mid	Buy-leaning	—	—	Ogsiveo (nirogacestat) for desmoid tumors; gamma-secretase inhibitor platform for rare oncology

16

Animal Health & Veterinary

Companion animal and livestock medicines, diagnostics, and vaccines — insulated from human drug pricing pressures and driven by pet-humanization trends.

Ticker	Company	Cap	Rating	Price	Target	What they do
ZTS	Zoetis	Large	Buy	~$183	—	World's largest animal health company: medicines, vaccines, diagnostics for livestock and companion animals
IDXX	IDEXX Laboratories	Large	Buy	—	—	In-house veterinary diagnostics (IDEXX Catalyst, ProCyte), reference labs, and point-of-care testing
ELAN	Elanco Animal Health	Mid	Hold	—	—	Companion animal and farm animal products; Credelio (parasiticide), Galliprant (canine pain)
PETQ	PetIQ	Small	Mixed	—	—	Affordable pet health and wellness products through retail and veterinary service distribution
PAHC	Phibro Animal Health	Small	Mixed	—	—	Medicated feed additives, vaccines, and performance enhancers for livestock and poultry

17

Women’s Health & Fertility

Contraception, fertility, menopause, endometriosis, and PCOS — historically underinvested specialty now attracting significant capital.

Ticker	Company	Cap	Rating	Price	Target	What they do
PGNY	Progyny	Mid	Buy-leaning	—	—	Fertility benefits management platform for employers; smart bundles covering IVF, egg freezing, surrogacy
HIMS	Hims & Hers Health	Small/Mid	Buy-leaning	—	—	Direct-to-consumer telehealth platform for men’s and women’s health (hair loss, sexual health, weight management)
DARE	Dare Bioscience	Small	Speculative	—	—	Women’s health drug pipeline: endometriosis, contraception, vaginal health therapeutics
MYOV	Myovant Sciences (now part of Sumitovant)	Large	Acquired	—	—	Myfembree/Orgoviyx (relugolix) for uterine fibroids and endometriosis; fully acquired by Sumitomo in 2023
ABBV	AbbVie (Orilissa/Oriahnn)	Large	Buy/Hold	~$195	—	Orilissa (endometriosis), Oriahnn (uterine fibroids) in addition to immunology blockbusters

18

Gastrointestinal & Inflammatory Bowel Disease

IBD biologics, NASH, liver disease, and the emerging RNA/small-molecule alternatives to TNF inhibitors.

Ticker	Company	Cap	Rating	Price	Target	What they do
ABVX	Abivax SA	Mid	Strong Buy	$96.15 (+37% 6/30)	~$108–$187 (avg ~$149)	Obefazimod Phase 3 for ulcerative colitis (NDA Q4 2026 target); RNA-based anti-inflammatory mechanism; remarkable 1,157% 1-yr gain
SYRE	Spyre Therapeutics	Small	Buy	—	~$115	Extended-half-life anti-integrin antibodies for IBD (Crohn’s & UC); Deutsche Bank initiated Buy $115 target
MDGL	Madrigal Pharmaceuticals	Mid	Buy	—	—	Rezdiffra (resmetirom) — first and only FDA-approved drug for NASH/MASH liver disease
ETNB	89bio	Small	Buy-leaning	—	—	Pegozafermin FGF21 analog for MASH and hypertriglyceridemia; Phase 3 stage
GILD	Gilead Sciences (liver)	Large	Buy-leaning	~$116	~$145	Hepatitis B & C treatments; seladelpar and GS-1670 for NASH; dominant viral liver disease franchise
ARWR	Arrowhead Pharmaceuticals	Mid	Buy	—	—	RNAi plozasiran targeting liver triglyceride production; NASH pipeline expansion

19

Renal & Nephrology

Dialysis services, IgA nephropathy, polycystic kidney disease, and the SGLT2 inhibitor wave redefining CKD management.

Ticker	Company	Cap	Rating	Price	Target	What they do
DVA	DaVita	Mid	Mixed	—	—	Largest independent U.S. kidney care/dialysis center network; outpatient and home dialysis
VERA	Vera Therapeutics	Small	Speculative	—	—	Atacicept TACI-Fc fusion protein for IgA nephropathy and lupus nephritis; Phase 3 ORIGIN trial
CALT	Calliditas Therapeutics	Small	Mixed	—	—	Tarpeyo/Nefecon (budesonide) FDA-approved for IgA nephropathy; first targeted therapy for this kidney disease
TVTX	Travere Therapeutics	Small	Buy-leaning	—	—	Filspari (sparsentan) for IgA nephropathy and FSGS; first non-immunosuppressant approved for IgAN
OTSKF	Otsuka Holdings (OTC)	Large	Mixed	—	—	Jynarque (tolvaptan) for autosomal dominant polycystic kidney disease (ADPKD)
KDNY	Chinook Therapeutics (now part of Novartis)	Small	Acquired 2023	—	—	Zibotentan/dapagliflozin combination for IgAN — pipeline assets acquired by Novartis in 2023

✅ BUY RATINGS

All 81 Companies with Buy or Strong Buy Consensus

Every company across all 19 specialties currently carrying a Buy or Strong Buy analyst consensus, sorted by conviction (Strong Buy → Buy → Buy-leaning) then alphabetically. Prices & targets as of June 29–30, 2026. Not investment advice. Not a recommendation to buy or sell.

#	TICKER	COMPANY	SPECIALTY	CAP	RATING	PRICE (Jun 30)	ANALYST TARGET	WHAT THEY DO
1	ABVX	Abivax SA	🧬 Biotech	Mid	Strong Buy	$96.15 (+37% today 6/30)	~$108–$187 (avg ~$149)	French clinical-stage biotech developing obefazimod, an RNA-targeting anti-inflammatory drug in Phase 3 for ul
2	CRDL	Cardiol Therapeutics	❤️ Cardiology	Small	Strong Buy	$0.99	~$8	Clinical-stage CBD-based anti-inflammatory heart drugs
3	ISRG	Intuitive Surgical	🤖 Robotics/MedTech	Large	Strong Buy	$412	~$580–$615	da Vinci & Ion robotic surgical platforms
4	LLY	Eli Lilly	💊 Large-Cap Pharma	Large (~$700B+)	Strong Buy	$1,117	~$1,220–$1,250	GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound)
5	ABT	Abbott Laboratories	❤️ Cardiology	Large	Buy	$92.71	~$128	Cardiovascular, diabetes & diagnostics conglomerate
6	ALNY	Alnylam Pharmaceuticals	🦋 Rare Disease	Large	Buy	—	—	RNAi pioneer; Onpattro, Givlaari, Oxlumo, Amvuttra (TTR amyloidosis cardiomyopathy) and growing commercial por
7	ARGX	argenx	🧬 Biotech	Mid	Buy	Check live price	—	FcRn blocker Vyvgart across autoimmune indications
8	ARWR	Arrowhead Pharmaceuticals	🦋 Rare Disease	Mid	Buy	—	—	RNAi therapeutics for rare liver disease (plozasiran for hypertriglyceridemia), respiratory, and cardiometabol
9	AXSM	Axsome Therapeutics	🧠 Neurology/CNS	Mid	Buy	—	—	Auvelity (MDD), Sunosi (narcolepsy/hypersomnia), Symbravo (migraine); CNS commercial-stage company
10	CRNX	Crinetics Pharmaceuticals	🧬 Biotech	Small	Buy	Check live price	—	Oral therapies for endocrine disorders
11	CRSP	CRISPR Therapeutics	🧬 Biotech	Mid	Buy	Check live price	—	Casgevy gene-editing therapy (with Vertex)
12	DXCM	DexCom	🩸 Diabetes Care	Mid	Buy	$71	~$64–$95	Continuous glucose monitoring (CGM) systems
13	GH	Guardant Health	🔬 Diagnostics	Mid	Buy	$140	—	Liquid biopsy cancer genomic testing
14	HCA	HCA Healthcare	🏥 Hospitals	Large	Buy	$315	~$415–$520	190+ acute-care hospitals across the U.S. & England
15	IDXX	IDEXX Laboratories	🐾 Animal Health	Large	Buy	—	—	In-house veterinary diagnostics (IDEXX Catalyst, ProCyte), reference labs, and point-of-care testing
16	JNJ	Johnson & Johnson (Abiomed & Shockwave)	❤️ Cardiology	Large	Buy	$254	~$257	Owns Impella heart pumps (Abiomed) and intravascular lithotripsy (Shockwave) for calcified artery treatment
17	KRYS	Krystal Biotech	🧬 Biotech	Mid	Buy	Check live price	—	Gene therapy gel Vyjuvek for rare skin disease
18	LEGN	Legend Biotech	🎗 Oncology	Mid	Buy	—	—	Carvykti BCMA CAR-T therapy (with J&J) for multiple myeloma
19	MDGL	Madrigal Pharmaceuticals	🫀 GI / IBD	Mid	Buy	—	—	Rezdiffra (resmetirom) — first and only FDA-approved drug for NASH/MASH liver disease
20	MDT	Medtronic	❤️ Cardiology	Large	Buy	$81	~$98–$108	Pacemakers, defibrillators, cardiac ablation tech
21	NTRA	Natera	🔬 Diagnostics	Mid	Buy	Check live price	—	Genetic testing, prenatal & oncology
22	NUVL	Nuvalent	🎗 Oncology	Mid	Buy	—	—	Next-generation kinase inhibitors for ROS1+ and ALK+ NSCLC; highly selective brain-penetrant design
23	PODD	Insulet	🩸 Diabetes Care	Mid	Buy	$154	~$190	Omnipod tubeless insulin pump
24	PRAX	Praxis Precision Medicine	🧠 Neurology/CNS	Small	Buy	—	—	Ion channel modulators for epilepsy and neuropsychiatric disorders; multiple late-stage assets
25	RARE	Ultragenyx Pharmaceutical	🦋 Rare Disease	Mid	Buy	—	—	Rare metabolic diseases; Crysvita (XLH), Dojolvi (LC-FAOD), Evkeeza (homozygous familial hypercholesterolemia)
26	RMD	ResMed	🫁 Respiratory	Large	Buy	~$244	—	CPAP/BiPAP devices and cloud-connected respiratory care platforms for sleep apnea and COPD
27	RVMD	Revolution Medicines	🎗 Oncology	Mid	Buy	—	—	RAS(ON) inhibitors targeting KRAS-driven cancers including pancreatic and colorectal
28	SYK	Stryker	🦴 Orthopedics	Large	Buy	$304.69	—	Orthopedic implants, Mako robotics, MedSurg
29	SYRE	Spyre Therapeutics	🫀 GI / IBD	Small	Buy	—	~$115	Extended-half-life anti-integrin antibodies for IBD (Crohn’s & UC); Deutsche Bank initiated Buy $115
30	TMO	Thermo Fisher Scientific	🔬 Diagnostics	Large	Buy	Check live price	—	Life sciences tools, diagnostics, lab equipment
31	TNDM	Tandem Diabetes Care	🩸 Diabetes Care	Small	Buy	$23	~$28–$31	t:slim X2 & Mobi insulin pumps
32	UNH	UnitedHealth Group	🛡️ Managed Care	Large	Buy	Check live price	~$357–$450	Largest U.S. insurer; UnitedHealthcare + Optum
33	VEEV	Veeva Systems	💻 Health IT	Large	Buy	Check live price	—	Cloud software for life sciences (CRM, regulatory)
34	VKTX	Viking Therapeutics	🧬 Biotech	Small	Buy	Check live price	—	Oral & injectable GLP-1 obesity candidates
35	VRNA	Verona Pharma	🫁 Respiratory	Mid	Buy	—	—	Ohtuvayre (ensifentrine) FDA-approved for COPD; first new COPD mechanism in 20 years
36	VRTX	Vertex Pharmaceuticals	🧬 Biotech	Large	Buy	Check live price	—	Cystic fibrosis monopoly, Casgevy gene therapy
37	XENE	Xenon Pharmaceuticals	🧬 Biotech	Small	Buy	Check live price	—	KV7 channel opener for epilepsy/neuro
38	ZTS	Zoetis	🐾 Animal Health	Large	Buy	~$183	—	World's largest animal health company: medicines, vaccines, diagnostics for livestock and companion animals
39	ABBV	AbbVie (Orilissa/Oriahnn)	🌸 Women's Health	Large	Buy/Hold	~$195	—	Orilissa (endometriosis), Oriahnn (uterine fibroids) in addition to immunology blockbusters
40	ACAD	ACADIA Pharmaceuticals	🧠 Neurology/CNS	Mid	Buy-leaning	—	—	Nuplazid (Parkinson's psychosis), Daybue (Rett syndrome), focused CNS rare-disease pipeline
41	ALC	Alcon	🦷 Dental & Vision	Large	Buy-leaning	Check live price	—	Surgical & vision care eye products
42	AMGN	Amgen	💊 Large-Cap Pharma	Large	Buy-leaning	Check live price	—	Immunology, oncology, obesity pipeline (MariTide)
43	AORT	Artivion (formerly CryoLife)	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Aortic disease devices, cardiac surgery grafts, and tissue products
44	ATEC	Alphatec Holdings	🦴 Orthopedics	Small	Buy-leaning	Check live price	—	Spine surgery technology
45	AXGN	Axogen	🦴 Orthopedics	Small	Buy-leaning	Check live price	—	Peripheral nerve repair
46	AZN	AstraZeneca	💊 Large-Cap Pharma	Large (~$291B)	Buy-leaning	Check live price	—	Oncology, cardiovascular/metabolic, biologics
47	BMRN	BioMarin Pharmaceutical	🦋 Rare Disease	Large	Buy-leaning	—	—	Enzyme replacement and gene therapies for rare genetic diseases: PKU, hemophilia A (Roctavian), achondroplasia
48	COO	The Cooper Companies	🦷 Dental & Vision	Large	Buy-leaning	Check live price	~$91	CooperVision contact lenses, CooperSurgical
49	CVS	CVS Health	🛡️ Managed Care	Large	Buy-leaning	Check live price	—	Retail pharmacy, Aetna insurance, Caremark PBM
50	DHR	Danaher	🔬 Diagnostics	Large	Buy-leaning	Check live price	—	Diagnostics, life sciences, biotech tools
51	EHC	Encompass Health	🏥 Hospitals	Mid	Buy-leaning	Check live price	—	Inpatient rehabilitation hospitals
52	ELV	Elevance Health	🛡️ Managed Care	Large	Buy/Neutral	Check live price	~$405	Blue Cross Blue Shield plans, Medicaid/MA
53	ETNB	89bio	🫀 GI / IBD	Small	Buy-leaning	—	—	Pegozafermin FGF21 analog for MASH and hypertriglyceridemia; Phase 3 stage
54	EXAS	Exact Sciences	🔬 Diagnostics	Mid	Buy-leaning	Check live price	—	Cancer screening (Cologuard)
55	GEHC	GE HealthCare	🔬 Diagnostics	Large	Buy-leaning	$63.72	—	MRI, CT, ultrasound imaging equipment
56	GILD	Gilead Sciences	💊 Large-Cap Pharma	Large	Buy-leaning	Check live price	—	HIV franchise, growing oncology (Trodelvy)
57	GMED	Globus Medical	🦴 Orthopedics	Mid	Buy-leaning	Check live price	—	Spine implants, ExcelsiusGPS robotic spine surgery
58	HAE	Haemonetics	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Blood management and autotransfusion systems used during cardiac surgery
59	HIMS	Hims & Hers Health	🌸 Women's Health	Small	Buy-leaning	—	—	Direct-to-consumer telehealth platform for men’s and women’s health (hair loss, sexual health, wei
60	INSP	Inspire Medical Systems	❤️ Cardiology	Mid	Buy-leaning	$41.75	—	Implantable neurostimulation for sleep apnea, a major cardiovascular risk factor
61	IONS	Ionis Pharmaceuticals	🧠 Neurology/CNS	Mid	Buy-leaning	—	—	Antisense oligonucleotide platform; Spinraza (SMA), eplontersen (TTR amyloidosis), broad neurology pipeline
62	IOVA	Iovance Biotherapeutics	🎗 Oncology	Mid	Buy-leaning	—	—	Amtagvi: first TIL (tumor-infiltrating lymphocyte) therapy approved by FDA for melanoma
63	IRTC	iRhythm Technologies	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Zio wearable patch for ambulatory cardiac arrhythmia monitoring
64	ITGR	Integer Holdings	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Manufactures components (batteries, leads) used inside pacemakers and defibrillators
65	LH	Labcorp	🔬 Diagnostics	Large	Buy-leaning	Check live price	—	Lab testing & drug development services
66	MMSI	Merit Medical Systems	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Cardiovascular catheters, guidewires, and embolization devices
67	MRK	Merck & Co.	🎗 Oncology	Large	Buy-leaning	~$113	~$122	Keytruda (#1 selling cancer drug globally), Gardasil HPV vaccine, facing 2028 patent cliff
68	MRUS	Merus	🎗 Oncology	Small	Buy-leaning	—	—	Bispecific antibody platform; Zenocutuzumab (NRG1 fusion cancers) recently FDA-approved
69	NARI	Inari Medical	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Catheter-based devices to remove blood clots in venous thromboembolism (DVT/PE)
70	NVST	Envista Holdings	🦷 Dental & Vision	Mid	Buy-leaning	$30	~$28	Nobel Biocare, Ormco, DEXIS dental brands
71	OMCL	Omnicell	💻 Health IT	Small	Buy-leaning	Check live price	—	Medication management automation
72	PEN	Penumbra ⚠ Acq. by BSX Jan 2026	❤️ Cardiology	Mid	Buy-leaning	$317.63	—	Thrombectomy systems for vascular and neurovascular clot removal
73	PGNY	Progyny	🌸 Women's Health	Mid	Buy-leaning	—	—	Fertility benefits management platform for employers; smart bundles covering IVF, egg freezing, surrogacy
74	RDNT	RadNet	🔬 Diagnostics	Small	Buy-leaning	$58	—	Outpatient imaging + AI imaging division
75	REGN	Regeneron Pharmaceuticals	🧬 Biotech	Large	Buy-leaning	Check live price	—	Eylea eye drug, Dupixent (with Sanofi)
76	RNA	Avidity Biosciences	🧬 Biotech	Small	Buy-leaning	Check live price	—	RNA-targeted therapeutics
77	SWTX	SpringWorks Therapeutics	🦋 Rare Disease	Small	Buy-leaning	—	—	Ogsiveo (nirogacestat) for desmoid tumors; gamma-secretase inhibitor platform for rare oncology
78	TMDX	TransMedics	🤖 Robotics/MedTech	Mid	Buy-leaning	Check live price	—	Organ transplant preservation/logistics tech
79	TVTX	Travere Therapeutics	💧 Renal	Small	Buy-leaning	—	—	Filspari (sparsentan) for IgA nephropathy and FSGS; first non-immunosuppressant approved for IgAN
80	UHS	Universal Health Services	🏥 Hospitals	Mid	Buy-leaning	Check live price	—	Acute care + behavioral health hospitals
81	WAY	Waystar Holding	💻 Health IT	Mid	Buy-leaning	Check live price	—	Healthcare payments & revenue cycle software

Sample Portfolio Mixes: Aggressive → Conservative

Four illustrative healthcare-sector tilts — purely educational examples of how the names above might be combined at different risk levels. Not a recommendation. These are hypothetical allocations for discussion purposes only and ignore your personal tax situation, time horizon, and existing holdings.

AGGRESSIVE

GROWTH

BALANCED

CONSERVATIVE

🔥 Aggressive Growth Mix

High volatility · binary catalysts · small/mid-cap heavy

25%Mid/small-cap biotech — ARGX (autoimmune drug Vyvgart), CRSP (gene editing), KRYS (gene therapy), VKTX (oral GLP-1)

20%Speculative cardio & gene-therapy — CRDL, OBIO, NTLA, SRPT

20%Digital health / AI diagnostics — TEM (AI precision medicine), DOCS (physician network), GH (liquid biopsy)

15%Emerging device disruptors — BBNX (bionic pancreas), ASXC (laparoscopic robotics), TMDX (organ transport)

20%High-growth large-cap anchor — ISRG (surgical robots), LLY (GLP-1 drugs)

📈 Growth-Tilted Mix

Established growth leaders · moderate volatility

20%GLP-1 / large-cap pharma growth (LLY, NVO, VRTX)

20%Surgical robotics (ISRG, MDT)

15%Diabetes devices (DXCM, PODD)

15%Diagnostics growth (GH, NTRA, EXAS)

15%Selective mid-cap biotech (ARGX, KRYS)

15%Managed care recovery play (UNH, HUM)

⚖️ Balanced Mix

Blend of growth and ballast across specialties

20%Diversified MedTech large-caps (MDT, SYK, ABT)

20%Large-cap pharma (JNJ, LLY, MRK)

15%Managed care (UNH, ELV)

15%Hospitals (HCA, UHS)

15%Diagnostics & labs (DGX, TMO)

15%Dental/vision & diabetes devices (COO, DXCM)

🛡️ Conservative / Defensive Mix

Dividend-payers · large, diversified, lower-beta names

30%Diversified pharma dividend payers (JNJ, ABBV, PFE)

25%Mega-cap MedTech (MDT, ABT)

20%Managed care blue-chip (UNH, ELV)

15%Hospital operator with scale (HCA)

10%Diagnostics utility-like cash flow (DGX, LH)

🚀 Emerging Companies With Potential Exponential Growth

Smaller, earlier-stage names pulled from across every specialty above that carry outsized — and outsized-risk — upside according to current Street commentary. These are higher-volatility, often pre-profit or single-catalyst companies. Treat this as a watchlist starting point, not a buy list.

Cardiology

CRDL — Cardiol Therapeutics

Strong Buy consensus from a small analyst panel; speculative CBD-based anti-inflammatory cardiac pipeline with Phase 3 catalysts ahead.

Cardiology

OBIO — Orchestra BioMed

Bioelectronic hypertension therapy partnered with Medtronic; binary upside tied to BACKBEAT trial data expected 2027.

Biotech

VKTX — Viking Therapeutics

Oral & injectable GLP-1 candidates; analysts flag among the highest implied upside in cardiometabolic biotech baskets.

Biotech

CRNX — Crinetics Pharmaceuticals

Oral endocrine-disorder therapies; high implied upside in recent genomics/biotech ETF rankings.

Biotech

XENE — Xenon Pharmaceuticals

KV7 channel opener for epilepsy/depression; William Blair 2026 top pick with late-stage data readouts on deck.

Biotech

KRYS — Krystal Biotech

Commercial-stage gene therapy (Vyjuvek) with a broader redosable gene-therapy platform; William Blair top pick.

Diagnostics

GH — Guardant Health

Biggest analyst-estimate beat among diagnostics peers in recent earnings; liquid biopsy/MRD growth story.

Diagnostics

RDNT — RadNet

Outpatient imaging network layering in an AI imaging division — a structural growth story beyond pure imaging volume.

Healthcare IT

TEM — Tempus AI

AI-driven precision medicine platform; high-growth, high-volatility name at the intersection of diagnostics and software.

Healthcare IT

WAY — Waystar Holding

Revenue-cycle/payments software riding hospital AI-automation adoption.

Robotics/MedTech

TMDX — TransMedics

Organ preservation & transplant logistics — building an end-to-end transplant ecosystem with first-mover scale.

Robotics/MedTech

ASXC — Asensus Surgical

Small-cap digital laparoscopic robotics name — high-risk, early-stage challenger to the ISRG/MDT duopoly.

Orthopedics

ATEC — Alphatec Holdings

Spine-focused challenger gaining share against legacy orthopedic majors with differentiated navigation tech.

Diabetes Care

BBNX — Beta Bionics

iLet bionic pancreas — newer entrant in automated insulin delivery still scaling commercial adoption.

Dental/Vision

NVST — Envista Holdings

Fastest revenue growth of its dental peer group last quarter, with consensus price target recently raised.

Compiled June 30, 2026 from stockanalysis.com, TipRanks, MarketBeat, Public.com, Simply Wall St, Investing.com, Zacks, Yahoo Finance, StockStory, and 24/7 Wall St.
Not investment advice. Not a recommendation to buy or sell any security. The author is not a financial advisor. Ratings and targets change frequently — verify current data before acting.